Absci (ABSI) Non-Current Deferred Tax Liability (2021 - 2024)
Absci (ABSI) posted Non-Current Deferred Tax Liability of $175000.0 for Q3 2024, little changed sequentially from $175000.0 in Q2 2024, and down 29.72% YoY from $249000.0 in Q4 2023.
Absci (ABSI) Non-Current Deferred Tax Liability (2021 - 2024) Analysis & Trends
Absci has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $175000.0 in Q3 2024.
- Quarterly Non-Current Deferred Tax Liability fell 29.72% year-over-year to $175000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $175000.0 (down 29.72% YoY) and the FY2023 annual result came in at $186000.0, down 21.85% from the prior year.
- Non-Current Deferred Tax Liability steadied at $175000.0 in Q3 2024 per ABSI's latest filing, from $175000.0 in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $5.2 million in Q2 2021 and troughed at $175000.0 in Q1 2024.
- A 4-year average of $1.0 million and a median of $243500.0 in 2022 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability sank 83.52% in 2023, then decreased 21.52% in 2024.
- Over 4 years, Non-Current Deferred Tax Liability stood at $743000.0 in 2021, then plunged by 67.97% to $238000.0 in 2022, then decreased by 21.85% to $186000.0 in 2023, then retreated by 5.91% to $175000.0 in 2024.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $175000.0, $175000.0, and $175000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 175,000.00 |
| Sep 30, 2024 | 175,000.00 |
| Jun 30, 2024 | 175,000.00 |
| Jun 30, 2024 | 175,000.00 |
| Mar 31, 2024 | 175,000.00 |
| Mar 31, 2024 | 175,000.00 |
| Dec 31, 2023 | 186,000.00 |
| Dec 31, 2023 | 186,000.00 |
| Sep 30, 2023 | 249,000.00 |
| Sep 30, 2023 | 249,000.00 |
| Jun 30, 2023 | 223,000.00 |
| Jun 30, 2023 | 223,000.00 |
| Mar 31, 2023 | 224,000.00 |
| Mar 31, 2023 | 224,000.00 |
| Dec 31, 2022 | 238,000.00 |
| Dec 31, 2022 | 238,000.00 |
| Sep 30, 2022 | 756,000.00 |
| Sep 30, 2022 | 756,000.00 |
| Jun 30, 2022 | 1.09 Mn |
| Jun 30, 2022 | 1.09 Mn |